The Indian vaccination programme against Covid-19 depended crucially on the Covishield vaccine produced by the Serum Institute of India and, to a lesser extent, on Bharat Biotech’s Covaxin. It has now been reported by this newspaper that both these companies have closed down some of their production lines and shifted resources to other vaccines, apparently because there are no more supply commitments. This cannot be viewed as unalloyed good news. While almost a billion first doses have been handed out in India, only 0.84 billion second doses have been administered as of Tuesday. In addition, only 12.3 million booster doses